Irreversible electroporation in a case of pancreatic leiomyosarcoma: a novel weapon versus a rare malignancy?
Alexandros PapalamprosMichail G VailasIoanna DeladetsimaDemetrios MorisMaria SotiropoulouAthanasios SyllaiosAthanasios PetrouEvangelos FelekourasPublished in: World journal of surgical oncology (2019)
In conclusion, primary pancreatic leiomyosarcoma is a rare and highly malignant tumor associated with poor prognosis. Nowadays, R0 surgical resection remains the cornerstone treatment, combined with adjuvant and/or neoadjuvant chemotherapy prior to resection. In the advanced setting, when major vessel invasion and distant metastases occur, chemotherapy along with irreversible electroporation ablation could be a helpful and possibly effective modality for the management of this highly aggressive tumor.